Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ACP-103 Clear all
Completed Phase 2 Interventional Results available

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

NCT01518309
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 1, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional

Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00658567
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
La Habra, California • Laguna Hills, California • Reseda, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 1, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional

Pimavanserin for Insomnia in Veterans With PTSD

NCT05441280
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Insomnia
Interventions
pimavanserin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

NCT03482882
View directory record Official record
Conditions
Treatment of Depression in Adults With Parkinson's Disease (PD)
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Costa Mesa, California • Fountain Valley, California • Pasadena, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

NCT02970305
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Phoenix, Arizona • Rogers, Arkansas • Bellflower, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

NCT03623321
View directory record Official record
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
60 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Gilbert, Arizona • Costa Mesa, California • Santa Ana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

NCT03575052
View directory record Official record
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
60 Years and older
Enrollment
784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Costa Mesa, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

NCT03018340
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
Pimavanserin, Placebo
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
36
States / cities
Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

NCT03118947
View directory record Official record
Conditions
Agitation and Aggression in Alzheimer's Disease
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Costa Mesa, California • Fresno, California • Fullerton, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 1, 2026, 10:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

NCT05555615
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 18 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

ACP-103 to Treat Parkinson's Disease

NCT00086294
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesias
Interventions
Intravenous Levodopa, ACP-103
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 1, 2026, 10:23 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

NCT07610135
View directory record Official record
Conditions
Mood (Psychological Function), Well Being, Mood, Healthy
Interventions
Psilocybin, Pimavanserin, Inactive Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

NCT00550238
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
83
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 1, 2026, 10:23 PM EDT